Mirviss Jeffrey B.'s Form 4 filing
Boston Scientific CorpBSX · filed Feb 13, 2025
- Accession no.
- 0001225208-25-001685
- Filed
- Feb 13, 2025
- Trade date
- Feb 11-12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $1.37M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mirviss Jeffrey B.CIK 0001566094 | Officer (EVP&Pres, Periph Intervent) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2025 | Common Stock | AGrant or awardAcquired | +23,760 | $0.00 | $0 | 52,214 | Direct | |
| Feb 11, 2025 | Common Stock | FTax withholdingDisposed | −10,738 | $105.98 | −$1,138,013.24 | 41,476 | Direct | |
| Feb 12, 2025 | Common Stock | SSaleDisposed | −13,022 | $105.06F3 | −$1,368,091.32 | 28,454 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.787 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.